Important information for our community:

   COVID-19 Resource Center  What to expect when you visit  
School of Nursing | HNH Fitness | Villa Marie Claire | Simulation Learning | About Holy Name | Careers | Support Holy Name

Medical Care

Patients & Visitors

About Holy Name Medical Center About Holy Name Medical Center

Key Phone Numbers

  • Medical Center Operator

  • 201-833-3000

  • Physician Referral Service

  • 877-HOLY-NAME (465-9626)

  • Patient Information

  • 201-833-3300

  • Foundation (Donations)

  • 201-833-3187

  • Human Resources

  • 201-833-7040

  • Medical Staff Office

  • 201-833-3352

View All Department Contact Numbers

For general questions or comments, email

For More Information:

Clinical Research

Select Semaglutide Study

Nearly half of all American adults have cardiovascular disease, making them more susceptible to a heart attack or stroke. Holy Name Medical Center is at the forefront of addressing this widespread condition with an array of advanced treatments for the disease, the number one killer of men and women in the U.S.

Holy Name is the only site in northern New Jersey offering the opportunity for eligible patients with cardiovascular disease to participate in the Select Semaglutide clinical study. This clinical trial is evaluating whether the medication, Semaglutide, is effective in preventing a recurrence of a cardiovascular event in patients who have suffered a heart attack, stroke or decreased circulation in their legs.

Semaglutide is approved by the Food and Drug Administration (FDA) to help control diabetes and has been shown to reduce the risk of cardiovascular events in those patients. The Select study is looking at whether the medication can reduce the risk in people who don't have diabetes but are mildly overweight and have cardiovascular disease. Semaglutide is added to whatever other medications might be used for controlling blood pressure and cholesterol.

"It has been shown that this medication causes mild weight loss and improvement of cholesterol when added to existing therapy in people with diabetes," said Dr. Thomas Birch, an internist and principal investigator of the study at Holy Name. "The Select study will evaluate whether it has the same effect on people without diabetes."

Individuals who think they might be eligible for this study should contact Holy Name's Institute for Clinical Research at 201-541-6312.